ChemDiv’s Russian arm wins Viriom HIV research contract

By Gareth Macdonald

- Last updated on GMT

Related tags: Clinical trial, Russia

ChemDiv’s subsidiary Chemical Diversity Research Institute (CDRI), based in Moscow, Russia, will carry out development work on a range of HIV antivirals on behalf of new drugmaker Viriom.

Viriom, also based in Russia, recently licensed development and commercialization rights to the candidate antivirals for the Russian, Belarusian, Ukrainian and Kazakhstani markets from Swiss drug major Roche.

Under the new agreement, CDRI will be responsible for clinical development of the compounds in a project that is expected to begin in 2010.

Irina Tyrnova, Viriom’s COO, told Outsourcing-pharma that CDRI’s 19-year track record of research, experienced staff and ability to provide a complete range of drug development services had won it the contract.

Tyrnova went on to say that the two compounds licensed from Roche have complete preclinical development profiles and are ready for Phase I trials. She added that Viriom is now preparing the necessary paperwork to begin the clinical programme.

In a press statement Vadim Bichko, ChemDiv’s VP of virology, said the: “HIV inhibitors have shown excellent antiviral properties in vitro, good bioavailability, PK and safety profiles, as well as a high genetic barrier to resistance.

Bichko added that, based on preclinical development work conducted so far, the compounds have the potential to become best in class HIV treatments.

In April ChemDiv significantly expanded its presence in Russia with the acquisition of local contract research organisation (CRO) Prudentas in a bid to increase access to the country's large pool of treatment naive patients.

HIV in the region

Last year a report by the United Nations’ HIV/AIDS monitoring group, UNAIDS, estimated that, in Russia alone, between 630,000 and 1.3 million people are infected with HIV.

These estimates differ significantly from the official position, as of June this year 494,074 cases were registered with the Russian authorities. However, which ever figures are correct it is clear that the Russian market for HIV treatments is substantial.

In the Ukraine the picture is similar. Current UNAIDS estimates suggest that 440,000 people live with HIV. In Belarus and Kazakhstan 13,000 and 12,000 citizens are thought to be infected by the virus.

Tyrnova also recognised the scale of the HIV epidemic in the region, describing the market as having “huge potential” but stressed that Viriom’s primary concern is the development of antivirals that help patients living with the disease.

She also explained that, in Russia, “[the development of] HIV treatment receives considerable support from the government​,” and added that Viriom wants the level of support to continue.

Related news

Show more

Related products

show more

Validating The Simoa Technology

Validating The Simoa Technology

Frontage Laboratories | 01-Oct-2019 | Technical / White Paper

Frontage is the first and only laboratory to validate Quanterix’ Simoa HD1 Analyzer for performing immunoassays. Most of the advanced instruments used...

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars